RA CAPITAL MANAGEMENT, L.P. — 13F Holdings & Portfolio
CIK 1346824 · latest 13F-HR filed 2026-05-15
RA CAPITAL MANAGEMENT, L.P. manages $9.44B in 13F-reported U.S. long-equity assets across 86 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are ASND (24.92%), PCVX (7.07%), RYTM (6.14%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 24 new positions, exited 10, added to 31, and trimmed 24.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$9.44B
Long-equity book
86
Distinct positions
2026-03-31
Filed 2026-05-15
+24 / −10 / ↑31 / ↓24
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- VAXCYTE INC$172.0M +34.8%
- ASCENDIS PHARMA A/S - ADR$159.3M +7.3%
- DIANTHUS THERAPEUTICS INC$152.8M +230.0%
- TYRA BIOSCIENCES INC$146.5M +45.7%
- NUVALENT INC-A$70.5M +37.3%
Top Trims
- RHYTHM PHARMACEUTICALS INC-$133.8M -18.7%
- WAVE LIFE SCIENCES LTD-$113.9M -36.8%
- PEPGEN INC-$95.1M -72.8%
- MINERALYS THERAPEUTICS INC-$57.4M -21.6%
- ARS PHARMACEUTICALS INC-$39.3M -31.1%
New Positions
- SPYGLASS PHARMA INC$207.8M
- ZAI LAB LTD-ADR$107.4M
- SAREPTA THERAPEUTICS INC$84.9M
- DAMORA THERAPEUTICS INC$62.1M
- XENCOR INC$59.1M
Exited Positions
- CIDARA THERAPEUTICS INC$743.4M
- AVIDITY BIOSCIENCES INC$623.3M
- ARCELLX INC$82.6M
- BELITE BIO INC - ADR$69.2M
- INVIVYD INC$42.3M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | ASCENDIS PHARMA A/S - ADR | ASND | 04351P101 | $2.35B | 24.92% | 10,281,496 | SH |
| 2 | VAXCYTE INC | PCVX | 92243G108 | $666.8M | 7.07% | 11,474,599 | SH |
| 3 | RHYTHM PHARMACEUTICALS INC | RYTM | 76243J105 | $579.8M | 6.14% | 6,666,837 | SH |
| 4 | TYRA BIOSCIENCES INC | TYRA | 90240B106 | $467.2M | 4.95% | 12,198,625 | SH |
| 5 | SIONNA THERAPEUTICS INC | SION | 829401108 | $397.1M | 4.21% | 9,905,045 | SH |
| 6 | EDGEWISE THERAPEUTICS INC | EWTX | 28036F105 | $328.5M | 3.48% | 10,428,437 | SH |
| 7 | NEWAMSTERDAM PHARMA CO NV | NAMS | N62509109 | $305.7M | 3.24% | 9,550,191 | SH |
| 8 | NUVALENT INC-A | NUVL | 670703107 | $259.6M | 2.75% | 2,534,145 | SH |
| 9 | DIANTHUS THERAPEUTICS INC | DNTH | 252828108 | $219.2M | 2.32% | 2,611,733 | SH |
| 10 | MINERALYS THERAPEUTICS INC | MLYS | 603170101 | $208.4M | 2.21% | 7,692,750 | SH |
| 11 | SPYGLASS PHARMA INC | SGP | 85220G109 | $207.8M | 2.20% | 8,021,117 | SH |
| 12 | WAVE LIFE SCIENCES LTD | WVE | Y95308105 | $195.6M | 2.07% | 26,975,505 | SH |
| 13 | SEPTERNA INC | SEPN | 81734D104 | $168.1M | 1.78% | 6,995,858 | SH |
| 14 | DISC MEDICINE INC | IRON | 254604101 | $156.7M | 1.66% | 2,450,221 | SH |
| 15 | JANUX THERAPEUTICS INC | JANX | 47103J105 | $155.5M | 1.65% | 11,189,693 | SH |
| 16 | BIOCRYST PHARMACEUTICALS INC | BCRX | 09058V103 | $150.7M | 1.60% | 15,827,186 | SH |
| 17 | BICARA THERAPEUTICS INC | BCAX | 055477103 | $144.3M | 1.53% | 7,255,993 | SH |
| 18 | PRAXIS PRECISION MEDICINES I | PRAX | 74006W207 | $120.4M | 1.28% | 373,787 | SH |
| 19 | GH RESEARCH PLC | GHRS | G3855L106 | $107.9M | 1.14% | 7,676,697 | SH |
| 20 | ZAI LAB LTD-ADR | ZLAB | 98887Q104 | $107.4M | 1.14% | 5,707,262 | SH |
| 21 | TAYSHA GENE THERAPIES INC | TSHA | 877619106 | $105.3M | 1.12% | 23,555,648 | SH |
| 22 | VOR BIOPHARMA INC | VOR | 929033207 | $96.4M | 1.02% | 5,404,998 | SH |
| 23 | GERON CORP | GERN | 374163103 | $95.0M | 1.01% | 63,771,366 | SH |
| 24 | ARS PHARMACEUTICALS INC | SPRY | 82835W108 | $87.2M | 0.92% | 10,860,977 | SH |
| 25 | SAREPTA THERAPEUTICS INC | SRPT | 803607100 | $84.9M | 0.90% | 3,902,596 | SH |
| 26 | SPYRE THERAPEUTICS INC | SYRE | 00773J202 | $81.8M | 0.87% | 1,621,620 | SH |
| 27 | EVOMMUNE INC | EVMN | 30054Y107 | $80.3M | 0.85% | 3,494,638 | SH |
| 28 | SOLID BIOSCIENCES INC | SLDB | 83422E204 | $67.2M | 0.71% | 9,339,978 | SH |
| 29 | ARTIVA BIOTHERAPEUTICS INC | ARTV | 04317A107 | $63.5M | 0.67% | 9,853,302 | SH |
| 30 | DAMORA THERAPEUTICS INC | DMRA | 36322Q206 | $62.1M | 0.66% | 2,399,310 | SH |
| 31 | CLIMB BIO INC | CLYM | 28658R106 | $60.4M | 0.64% | 8,821,067 | SH |
| 32 | XENCOR INC | XNCR | 98401F105 | $59.1M | 0.63% | 4,897,237 | SH |
| 33 | LB PHARMACEUTICALS INC | LBRX | 50180M108 | $54.5M | 0.58% | 2,208,604 | SH |
| 34 | JADE BIOSCIENCES INC | JBIO | 008064206 | $51.6M | 0.55% | 3,671,083 | SH |
| 35 | ACUMEN PHARMACEUTICALS INC | ABOS | 00509G209 | $49.5M | 0.52% | 20,992,669 | SH |
| 36 | 4D MOLECULAR THERAPEUTICS IN | FDMT | 35104E100 | $47.0M | 0.50% | 5,049,779 | SH |
| 37 | FULCRUM THERAPEUTICS INC | FULC | 359616109 | $46.4M | 0.49% | 6,053,960 | SH |
| 38 | CAPRICOR THERAPEUTICS INC | CAPR | 14070B309 | $45.8M | 0.49% | 1,507,844 | SH |
| 39 | CENTURY THERAPEUTICS INC | IPSC | 15673T100 | $40.1M | 0.43% | 17,754,430 | SH |
| 40 | OLEMA PHARMACEUTICALS INC | OLMA | 68062P106 | $38.8M | 0.41% | 2,600,000 | SH |
| 41 | LENZ THERAPEUTICS INC | LENZ | 52635N103 | $38.2M | 0.41% | 4,178,823 | SH |
| 42 | MONOPAR THERAPEUTICS INC | MNPR | 61023L207 | $36.6M | 0.39% | 667,207 | SH |
| 43 | PEPGEN INC | PEPG | 713317105 | $35.5M | 0.38% | 20,064,545 | SH |
| 44 | DESIGN THERAPEUTICS INC | DSGN | 25056L103 | $31.6M | 0.34% | 2,972,973 | SH |
| 45 | MIRUM PHARMACEUTICALS INC | MIRM | 604749101 | $29.4M | 0.31% | 318,554 | SH |
| 46 | BIOAGE LABS INC | BIOA | 09077V100 | $28.9M | 0.31% | 1,650,648 | SH |
| 47 | LEXEO THERAPEUTICS INC | LXEO | 52886X107 | $28.7M | 0.30% | 5,000,000 | SH |
| 48 | ASSEMBLY BIOSCIENCES INC | ASMB | 045396207 | $28.3M | 0.30% | 1,020,410 | SH |
| 49 | REZOLUTE INC | RZLT | 76200L309 | $28.0M | 0.30% | 9,180,000 | SH |
| 50 | AKTIS ONCOLOGY INC | AKTS | 01021M104 | $26.9M | 0.28% | 1,503,084 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | $9.44B | 86 | 0001104659-26-062637 |
| 2025-12-31 | 2026-02-17 | $9.76B | 72 | 0001104659-26-016482 |
| 2025-09-30 | 2025-11-14 | $8.12B | 68 | 0001104659-25-112469 |